Mr. Knight is a Senior Equity Research Analyst, Managing Director, and Head of Healthcare Research at Janney Montgomery Scott. He covers the life science technology industry, including the segments of instrumentation, genomics and diagnostics industries. He has over 25 years of equity research experience.

Prior to joining Janney in 2013, Paul Knight was an Analyst at CLSA Americas, LLC, where he gained extensive on-the-ground experience in Asia. He was also a founding partner of Thomas Weisel Partners and held positions at Salomon Brothers and NatWest Securities. His investment experience also includes work as a Political Analyst in Washington, D.C. and the first life science focused coverage of Agilent, Danaher, Thermo Fisher, among others.

Paul has been ranked over 10 times by the investment polls of The Wall Street Journal, Institutional Investor, and Greenwich Associates. He has consulted with technology commercialization advisors for The Massachusetts Institute of Technology (MIT) and the Rockefeller Institute. A frequent speaker at industry conferences and events, he has been a guest speaker on economics, finance, and industry trends at the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy as well as conferences hosted by the American Chemistry Society and Analytical and Life Sciences Industry Association. Mr. Knight frequently authors industry research reports, including his recent report titled “Another Epic Healthcare Era,” which provides data that record drug discovery rates are likely to continue and biopharmaceutical research and development will increase.

Paul is a Chartered Financial Analyst charterholder. He earned his B.B.A. in Economics from the University of Nebraska-Lincoln and his M.B.A. in Finance from The George Washington University School of Business.

For a list of companies covered by Paul Knight, consult Janney's Research Universe



  • CFA®

To learn about the professional background, business practices, and conduct of FINRA member firms or their financial professionals, visit FINRA’s BrokerCheck website: http://brokercheck.finra.org/